Efficacy and safety of cytokines versus first-line sunitinib and second-line axitinib for patients with metastatic renal cell carcinoma (ESCAPE study): A study protocol for phase III randomized sequential open-label study-Reference-Cited by-同舟云学术

Efficacy and safety of cytokines versus first-line sunitinib and second-line axitinib for patients with metastatic renal cell carcinoma (ESCAPE study): A study protocol for phase III randomized sequential open-label study

Published:2019-09 Issue: Volume:15 Page:100403
ISSN:2451-8654
Container-title:Contemporary Clinical Trials Communications
language:en
Short-container-title:Contemporary Clinical Trials Communications

Author:

Kadono Yoshifumi,Konaka Hiroyuki,Izumi Kouji,Anai Satoshi,Fujimoto Kiyohide,Ishibashi Kei,Kawai Noriyasu,Kato Taku,Iba Akinori,Masumori Naoya,Yoshimura Kenichi,Mizokami Atsushiu

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference25 articles.

1. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N. Engl. J. Med.,2007

2. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial;Rini;Lancet,2011

3. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial;Sternberg;J. Clin. Oncol.,2010

4. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study;Heng;J. Clin. Oncol.,2009

5. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma;Motzer;J. Clin. Oncol.,2004

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of First-Line Cytokines Versus Sunitinib and Second-Line Axitinib for Patients with Metastatic Renal Cell Carcinoma (ESCAPE Study): A Phase III, Randomized, Sequential Open-Label Study;Cancers;2023-05-13

2. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis;Cochrane Database of Systematic Reviews;2023-05-04

3. Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis;European Journal of Cancer;2021-09

4. Sequential treatment of metastatic renal cancer in a complex evolving landscape;Annals of Translational Medicine;2019-12